

MONTHLY MEDICATION SAFETY UPDATE

Information for health professionals in NSW public health organisations

This is a summary of medication safety and supply related issues affecting NSW public health facilities in **June 2026**. Updates regarding current medication-specific safety and supply related issues are available on the [CEC website](#).

Medication Safety and Supply Summary

41	Safety/supply issues requiring investigation by the CEC
11	Reported to the frontline due to safety risk requiring local mitigation
0	Formal safety communication developed
4	Previous issues resolved on CEC Medication Safety Updates table

Medications reported on CEC Medication Safety Updates table this month:

- Andexanet alfa powder for injection
- Cefuroxime 125 mg/5 mL oral suspension
- Dantrolene sodium hemiheptahydrate 20 mg powder for injection vial
- Ferric carboxymaltose injection
- Gastrografin and Urografin contrast agents (amidotrizoate meglumine and sodium amidotrizoate)
- Glyceryl trinitrate 300 microg sublingual tablets
- Hydralazine 20 mg injection
- Insulin – multiple products
- Multivitamin liquid for infants (Pentavite)
- Pamidronate 30 mg/10 mL injection vial
- Promethazine 50 mg/2 mL injection ampoule

NSQHS Standards (third edition) – Public consultation

The Commission is seeking feedback on the initial draft of the [NSQHS Standards \(third edition\)](#), including whether they:

- reflect key safety and quality priorities
- clearly describe expectations for health service organisations
- support the delivery of high-quality care
- reduce compliance burden while maintaining safety and quality
- are clear, easy to understand and free from unnecessary duplication.

Feedback on the third edition closes on **Friday 25 September 2026**. Please refer to the Commission [website](#) for more information on how to submit feedback.

CEC updates:

- The CEC, with the expertise of the Paediatric Venous Thromboembolism (VTE) Working Group has developed and endorsed a new [Paediatric VTE Risk Assessment Tool](#). This tool supports assessment of paediatric inpatients admitted to NSW Health facilities.
- NSW High Consequence Infectious Diseases (HCID) medicines have been added to the REALM. Please see [latest update](#) for more information.
- The CEC has recently published an [Argipressin factsheet](#) to provide advice on the use of argipressin 20 units/1 mL injection products, including products on the Australian Register of Therapeutic Goods (ARTG) and unapproved products accessed via the TGA Special Access Scheme (SAS).
- The CEC is revising the NSW Health Policy Directive *Patient Identification Bands* (PD2021_033) and is seeking feedback on the draft. Comments close **COB 14 August 2026** via the CEC ["Have Your Say"](#) page.

Therapeutic Goods Administration (TGA) updates:

- *Major or ongoing medication shortages:*
 - [Creon \(pancreatic extract\) capsules shortage extended](#).
- *Product Information safety updates:* [June 2026](#)
- *Safety alerts:*
 - [Unapproved ibutamoren capsules \(MK-677\) found to contain undisclosed anabolic steroid](#).
 - [Sexual enhancement supplements found to contain undeclared prescription medicines](#).
 - The TGA Laboratory has tested a product labelled [Grakcu](#) and found that the capsules contained undeclared medicines sildenafil and tadalafil.
 - [GLP-1 RAs and rare, but severe, eye disorders](#).
- *Market Actions:*
 - [Nature's Own Glucosamine Sulfate with Chondroitin and Nature's Own Magnesium Glycinate 1150 mg](#) – recall of two batches due to potential presence of a glass fragment within the bottle (not within the tablets).

If you need support or assistance with medication safety matters in your facility, please email us:
CEC-MedicationSafety@health.nsw.gov.au